Related Experiment Videos

Protein tyrosine phosphatase 1B inhibitors for diabetes

Theodore O Johnson1, Jacques Ermolieff, Michael R Jirousek

  • 1Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, USA.

Nature Reviews. Drug Discovery
|September 5, 2002
PubMed

Insights

New treatments are needed for type 2 diabetes and obesity. Protein tyrosine phosphatase 1B (PTP1B) is a potential target for drugs aimed at improving insulin and leptin resistance.

Area of Science:

  • Biochemistry
  • Metabolic Diseases
  • Pharmacology

Background:

  • Rising rates of type 2 diabetes mellitus and obesity highlight the need for novel therapeutic agents.
  • Insulin and leptin resistance are key features of both type 2 diabetes and obesity.
  • Agents that can overcome this resistance may offer effective treatments for these conditions.

Purpose of the Study:

  • To review protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for type 2 diabetes.
  • To discuss the challenges associated with developing small-molecule inhibitors for PTP1B.

Main Methods:

  • Literature review of PTP1B's role in insulin and leptin signaling.
  • Analysis of current research on small-molecule PTP1B inhibitors.

Main Results:

  • PTP1B acts as a negative regulator in insulin and leptin signal transduction pathways.
  • Developing effective and selective small-molecule inhibitors for PTP1B presents significant challenges.

Conclusions:

  • PTP1B is a promising novel target for the treatment of type 2 diabetes and potentially obesity.
  • Further research is needed to overcome the hurdles in developing PTP1B-targeted therapies.

Related Concept Videos